DiaSorin
| Società per azioni | |
| Traded as | BIT: DIA |
| Industry | Biotechnology |
| Founded | 1968 |
| Headquarters | Saluggia, Italy |
Key people |
Gustavo Denegri (Chairman) Carlo Rosa (CEO) |
| Products | In vitro diagnostics instruments and services |
| Revenue |
 €443.8 million[1] (2014) |
Number of employees | 1,620 (2014)[1] |
| Website |
www |
DiaSorin is an Italian multinational biotechnology company that produces and markets in vitro diagnostics reagent kits used in immunodiagnostics and molecular diagnostics.[2] The group was founded in 1968 and is headquartered in Saluggia (Italy).
The production platform of the Group is now divided into several plants located in Europe, the United States and Africa: Saluggia, Dietzenbach (Germany), Stillwater, Minnesota (USA), Dublin (Ireland), Dartford (UK) and Kyalami (South Africa).[1]
The company is a constituent of the FTSE Italia Mid Cap index.
In March 2016, the company announced it would acquire Quest Diagnostics’ Focus Diagnostics immunodiagnostic and molecular diagnostic division for $300 million.[3]
Activities
DiaSorin is focusing its efforts to 8 fields of immunodiagnostics: Infectious diseases, Bone and Mineral, Endocrinology, Hypertension, Oncology, Gastro-Intestinal infections, Autoimmunity and Brain and Cardiac markers.
The company is also active in molecular diagnostics for infectious diseases and for the detection of some forms of Leukemia.[1]
Shareholder base
| Shareholder (2015[4]) | Share % |
|---|---|
| Finde SS | 43.957% |
| Rosa Carlo | 8.540% |
| Oppenheimerfunds Inc, | 4.800% |
| Even Chen Menachem | 4.466% |
| Threadneedle Asset Management Holdings Ltd | 3.690% |
| Market | 34.547% |
Financial data
DiaSorin is listed since 2007 in the Italian Stock Exchange and today in the FTSE Italy Mid Cap Index.
| (in thousand Euros)[1] | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 |
|---|---|---|---|---|---|---|---|---|
| Sales and service revenues | 206,367 | 244,612 | 304,129 | 404,547 | 440,003 | 433,763 | 434,849 | 443,770 |
| Cost of sales | (73,827) | (84,010) | (90,484) | (119,812) | (126,145) | (136,420) | (135,187) | (145,032) |
| Gross profit | 132,540 | 160,602 | 213,645 | 284,735 | 313,858 | 297,343 | 299,662 | 298,738 |
| EBIT | 47,576 | 70,790 | 106,438 | 145,517 | 163,307 | 140,259 | 134,693 | 129,891 |
| Profit before taxes | 44,135 | 59,887 | 103,733 | 144,932 | 158,256 | 137,406 | 129,339 | 128,124 |
| Net result | 26,367 | 37,459 | 70,047 | 90,418 | 99,607 | 87,684 | 83,111 | 84,074 |
| EBITDA | 61,519 | 85,618 | 123,636 | 167,112 | 190,020 | 169,558 | 163,098 | 160,290 |
Notes
- 1 2 3 4 5 "Annual Financial Report at December 31, 2014". Retrieved 3 July 2015.
- ↑ "About us". Retrieved 24 November 2013.
- ↑ "DiaSorin to Acquire Quest's Focus Diagnostics for $300M". GEN.
- ↑ "Diasorin official website, At a glance". Retrieved 8 July 2015.